The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Docetaxel (DOC) versus new androgen receptor-targeted agent (ART) in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) having received abiraterone (ABI) or enzalutamide (ENZA) as first-line (L1).
 
Antonin Broyelle
No Relationships to Disclose
 
André-Michel Bimbai
No Relationships to Disclose
 
Aurelien Carnot
Honoraria - Pfizer
Research Funding - Pfizer; PledPharma; Vifor Pharma
Expert Testimony - Amgen
Travel, Accommodations, Expenses - Merck; MSD
 
Diane Pannier
Expert Testimony - Amgen; SERVIER
Travel, Accommodations, Expenses - Astellas Oncology; Ipsen; MSD
 
Samira Makhloufi
No Relationships to Disclose
 
Thomas Ryckewaert
No Relationships to Disclose
 
Nicolas Penel
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Janssen-Cilag
Other Relationship - PharmaMar
 
Stephane Oudard
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD Oncology; MSD Oncology; Novartis; Pfizer; Roche; Roche; Sanofi
Research Funding - Ipsen; Sanofi
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck; MSD Oncology; Novartis; Pfizer; Roche